Journal article

Determining the efficacy and tolerance of quetiapine extended release for the management of psychosis and accompanying acute behavioral disturbance in adult acute psychiatry

Stuart J Lee, Fiona Foley, Erica Hannagan, Jayashri Kulkarni, Peter Bosanac, David J Castle, Yitzchak Hollander

Annals of Clinical Psychiatry | QUADRANT HEALTHCOM INC | Published : 2012

Abstract

BACKGROUND: This study was conducted to explore the efficacy and tolerability of quetiapine extended release (XR) to treat psychosis and accompanying acute behavioral disturbance in hospitalized psychiatric patients. METHODS: Patients with psychosis who displayed aggression were administered quetiapine XR (day 1 mean dose: 293.3 mg). Symptoms and side effects were assessed prospectively over an 8-day period. Symptoms were measured by the Overt Aggression Scale and Brief Psychiatric Rating Scale (BPRS), and side effects were measured using the Simpson-Angus Scale and Barnes Akathisia Rating Scale. RESULTS: Fifteen of 16 consenting patients completed the study. Aggression was significantly red..

View full abstract

Grants

Awarded by AstraZeneca Australia


Funding Acknowledgements

Funding for the conduct of this investigator-initiated study was provided by AstraZeneca Australia (Study Code: D1443C00043). The authors would like to thank research assistants Matt Donato and Sara Greenbaum who conducted recruitment for this project.Dr. Kulkarni receives grant or research support from AstraZeneca, the Australian Research Council, Brain Resource Centre, Department of Health (Victoria, Australia), Department of Justice (Victoria, Australia), Eli Lilly and Company, Hospira, JanssenCilag, National Health and Medical Research Council (Australia), and the Stanley Medical Research Institute; is a consultant to Janssen-Cilag and Lundbeck; and is a speaker for Eli Lilly and Company, Janssen-Cilag, and Lundbeck. Dr. Bosanac receives grant or research support from AstraZeneca. Dr. Castle receives grant or research support from Allergen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Hospira, JanssenCilag, Lundbeck, Pfizer, and Roche. Dr. Hollander receives grant or research support from AstraZeneca. Dr. Lee, Ms. Foley, and Ms. Hannagan report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.